Part I – The clinical trial landscape of the Asia-Pacific, Japan

On the heels of our recent post on our presence at this week’s DIA Japan 2015, BBK welcomes Philip Gregory, the General Manager of George Clinical – CRO China as our guest contributor. With more than 20 years of experience in pharmaceutical, biotech and medical device marketing, Mr. Gregory has spent over 14 years supporting the […]

Read More

Lowering blood pressure to decrease risk of cardiovascular events

Globally, there are millions of people that could benefit from an intensive lowering of blood pressure (BP). An individual with lower BP decreases their chances of suffering from any cardiovascular events such as: stroke, heart disease or heart attacks. A new study shows that lowering blood pressure to less than 140 mm Hg, the current […]

Read More

Diabetes warning signs even healthy women needs to heed

If you haven’t thought about diabetes before, it is time to stop and think for a minute. Why, you might ask? The World Health Organization’s figures from last year estimate over 350 million people worldwide have diabetes. The emerging epidemic is attributed to the rapid increases in overweight, obese and physically inactive individuals. Diabetes is […]

Read More

Record-setting metrics for Chinese Phase III Diabetes Study

Access to large markets where clinical trials that can investigate real patient needs, and do so in a rapid fashion, is invaluable for clinical research organisations.  One such example of George Clinical rapid and access to huge markets took place in China, where diabetes patients numbered up to 90 million in 2010, and the most […]

Read More

COPD and its co-morbidities

COPD is one of the world’s leading cause of death with prevalence ranging from 6% to 19% globally. This disease is particularly relevant for us in Asia-Pacific as risk factors such as smoking, biomass fuels, TB and air pollution are more prevalent than other regions. For example COPD prevalence in Chinese males is estimated to […]

Read More

Benefits of DPPIV-inhibitors still uncertain

The recent SAVOR-TIMI 53 (saxagliptin) and EXAMINE (alogliptin) trials recently reported the effects of the DPPIV inhibitor class of glucose lowering agents in people with diabetes. As required by the US FDA, both drugs were found not to increase cardiovascular risk, allowing the agents to be registered for use in that country. Good news, it would […]

Read More

Twitter Facebook LinkedIn